BioSpace News Archive

Maxar Technologies (NYSE:MAXR) (TSX:MAXR), provider of comprehensive space solutions and secure, precise, geospatial intelligence, announced it received a Phase A study contract from NASA for the National Oceanic and Atmospheric Administration’s (NOAA) Geostationary Extended Observations (GeoXO) Spacecraft mission.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the second quarter ended June 30, 2022.

ProPhase Labs, Inc., a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on Thursday, August 11, 2022 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30,2022.

Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its supplemental New Drug Application for NUPLAZID® for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

Geron Corporation announced that it will release its second quarter 2022 financial results after the market closes on Thursday, August 11, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

Sosei Group Corporation, the world leader in G protein-coupled receptor focused structure-based drug design and development, has been notified by its partner Neurocrine Biosciences Inc. that the U.S. Food and Drug Administration Investigational New Drug Application for a Phase 2 clinical trial of NBI-1117568 for the treatment of schizophrenia has been accepted by the FDA and that the study may proceed.

Marker Therapeutics, Inc. (Nasdaq: MRKR), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for MT-601, a multi-tumor-associated antigen (multiTAA)-specific T cell product targeting six antigens, for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 42nd Annual Growth Conference.

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022.